Stay updated on UBX1325 Safety in Macular Disease Clinical Trial
Sign up to get notified when there's something new on the UBX1325 Safety in Macular Disease Clinical Trial page.

Latest updates to the UBX1325 Safety in Macular Disease Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page now presents the study record for the UBX1325 Phase 1 safety and tolerability trial in patients with diabetic macular edema or neovascular age-related macular degeneration, including its study details and participant criteria.SummaryDifference41%

- Check14 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the displayed study record still shows a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedAn NIH-wide banner announces a website transition and says some NIH content may use “Super Intelligence” instead of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check35 days agoChange DetectedThe site footer’s revision number changed from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe study page displays a 403 Forbidden message with a Home link instead of study information.SummaryDifference0.5%

Stay in the know with updates to UBX1325 Safety in Macular Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the UBX1325 Safety in Macular Disease Clinical Trial page.